- Home
- NUWE vs PCSA Comparison
NUWE vs PCSA Comparison
Compare NUWE & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUWE
- PCSA
- Stock Information
- Founded
- NUWE 1999
- PCSA 2011
- Country
- NUWE United States
- PCSA United States
- Employees
- NUWE N/A
- PCSA N/A
- Industry
- NUWE Biotechnology: Electromedical & Electrotherapeutic Apparatus
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- NUWE Health Care
- PCSA Health Care
- Exchange
- NUWE Nasdaq
- PCSA Nasdaq
- Market Cap
- NUWE 3.9M
- PCSA 3.3M
- IPO Year
- NUWE N/A
- PCSA N/A
- Fundamental
- Price
- NUWE $4.18
- PCSA $0.19
- Analyst Decision
- NUWE
- PCSA Strong Buy
- Analyst Count
- NUWE 0
- PCSA 1
- Target Price
- NUWE N/A
- PCSA $1.00
- AVG Volume (30 Days)
- NUWE 203.8K
- PCSA 2.3M
- Earning Date
- NUWE 11-10-2025
- PCSA 10-29-2025
- Dividend Yield
- NUWE N/A
- PCSA N/A
- EPS Growth
- NUWE N/A
- PCSA N/A
- EPS
- NUWE N/A
- PCSA N/A
- Revenue
- NUWE $8,318,000.00
- PCSA N/A
- Revenue This Year
- NUWE $6.53
- PCSA N/A
- Revenue Next Year
- NUWE $51.63
- PCSA N/A
- P/E Ratio
- NUWE N/A
- PCSA N/A
- Revenue Growth
- NUWE N/A
- PCSA N/A
- 52 Week Low
- NUWE $3.74
- PCSA $0.15
- 52 Week High
- NUWE $175.98
- PCSA $1.50
- Technical
- Relative Strength Index (RSI)
- NUWE 28.16
- PCSA 42.95
- Support Level
- NUWE $3.74
- PCSA $0.16
- Resistance Level
- NUWE $4.35
- PCSA $0.20
- Average True Range (ATR)
- NUWE 0.26
- PCSA 0.02
- MACD
- NUWE 0.14
- PCSA 0.00
- Stochastic Oscillator
- NUWE 27.16
- PCSA 44.66
About NUWE Nuwellis Inc.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).